project id: TCGA-PRAD; case submitter id: TCGA-EJ-AB27; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.59; rna integrity number: 9.1; age at index: 51; days to birth: -18648; ethnicity: not reported; gender: male; race: white; vital status: Alive; year of birth: 1962; age at diagnosis: 18648; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 145.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 130; initial weight: 490.0; sample id: 9e579a4b-7f6b-4e1b-9b68-169d7e104b26; sample submitter id: TCGA-EJ-AB27-01A; portion id: 349919c0-7846-41d6-af26-45ac208a86ee; portion submitter id: TCGA-EJ-AB27-01A-11; slide id: f77f4813-6967-431b-925f-f973f3f0f18e; slide submitter id: TCGA-EJ-AB27-01A-01-TSA; percent lymphocyte infiltration: 4.0; percent monocyte infiltration: 0.0; percent necrosis: 2.0; percent neutrophil infiltration: 0.0; percent normal cells: 2.0; percent stromal cells: 38.0; percent tumor cells: 58.0; percent tumor nuclei: 90.0; section location: TOP;